FIA
MYGN icon

FNY Investment Advisers’s Myriad Genetics MYGN Stock Holding History

FNY Investment Advisers’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,930
Closed -$21.2K – 1267
2025
Q3 		$21K Buy
+2,930
New +$17.4K 0.01% 673
2019
Q3 		– Sell
-1,250
Closed -$34K – 1062
2019
Q2 		$34K Buy
+1,250
New +$35.3K 0.01% 416

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

FNY Investment Advisers's MYGN Position: Q4 2025 in Review

FNY Investment Advisers sold out of Myriad Genetics (MYGN) in Q4 2025, closing a stake of 2,930 shares — an estimated $21.2K sold.

FNY Investment Advisers first reported a position in MYGN in Q2 2019 and held it in 2 quarters. The position peaked at $34K in Q2 2019. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2025.

  • FNY Investment Advisers reported no remaining Myriad Genetics position as of Q4 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 2,930 Myriad Genetics shares in Q4 2025, an estimated $21.2K.
  • FNY Investment Advisers first reported a position in Myriad Genetics in Q2 2019 and held it in 2 quarters.
  • FNY Investment Advisers's Myriad Genetics position peaked at $34K in Q2 2019.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2025.

Based on FNY Investment Advisers's 13F filing for Q4 2025, filed 16 Jan 2026.